Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC
A Randomized, Parallel Control, Exploratory Trial to Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in Subjects With Advanced or Metastatic of the Non-small Cell Lung Cancer (NSCLC)
Sponsor: Fuzhou General Hospital
Terminated
Due to the enrollment was slow and exceeded the expected enrollment time
Listed as NCT03256721, this PHASE2 trial focuses on Nonsmall Cell Lung Cancer and remains terminated or withdrawn. Sponsored by Fuzhou General Hospital, it has been updated 7 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Mar 2021 — Jul 2024 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
-
Jan 2021 — Mar 2021 [monthly]
Unknown Status PHASE2
-
Sep 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Aug 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fuzhou General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .